Summary
Pfizer Inc. (PFE) announced the completion of a substantial public offering of senior notes on September 7, 2018, raising a total of $5.7 billion. This offering included a mix of floating rate notes and fixed-rate notes with maturities ranging from 2021 to 2048, indicating Pfizer's strategy to manage its capital structure and secure long-term funding. The company utilized its existing shelf registration statement to facilitate this debt issuance. The proceeds from this offering are not explicitly stated for a particular use in this filing, but such issuances are typically used for general corporate purposes, including potential acquisitions, debt refinancing, research and development, or capital expenditures. Investors should note this significant increase in Pfizer's long-term debt obligations.
Key Highlights
- 1Pfizer Inc. completed a public offering of notes totaling $5.7 billion.
- 2The offering included various tranches of fixed-rate notes with maturities in 2021, 2023, 2028, 2038, and 2048.
- 3A $300 million tranche of Floating Rate Notes due 2023 was also issued.
- 4The debt issuance was conducted under Pfizer's shelf registration statement filed earlier in 2018.
- 5Underwriting agreements and related pricing agreements were entered into on September 4, 2018, with major financial institutions.
- 6Indentures establishing the terms and conditions of the notes were finalized on September 7, 2018, with The Bank of New York Mellon serving as trustee.
- 7The filing includes various exhibits related to the offering, such as underwriting agreements, indentures, forms of notes, and a legal opinion.